MARKET

PLX

PLX

Protalix Biother
AMEX
2.830
+0.040
+1.43%
After Hours: 2.930 +0.1 +3.53% 19:23 03/13 EDT
OPEN
2.820
PREV CLOSE
2.790
HIGH
2.880
LOW
2.780
VOLUME
705.60K
TURNOVER
--
52 WEEK HIGH
3.190
52 WEEK LOW
1.320
MARKET CAP
227.59M
P/E (TTM)
61.39
1D
5D
1M
3M
1Y
5Y
1D
European Commission Approves J&J Prostate Drug, PLX Fabry Dosing, Incyte's Zynyz Second Indication
NASDAQ · 1d ago
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
PR Newswire · 3d ago
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Sangamo Biosciences (SGMO) and Protalix (PLX)
TipRanks · 4d ago
Protalix Gains EU Approval for Extended Elfabrio Dosing
TipRanks · 5d ago
Protalix, Chiesi Global Rare Diseases: EC approves dosing regimen for Elfabrio
TipRanks · 5d ago
The European Commission Approves 2mg/kg Every-4-weeks Dosing Regimen For Chiesi And Protalix Biotherapeutics' Elfabrio (Pegunigalsidase Alfa) For Fabry Disease Patients Who Are Stable With An Enzyme Replacement Therapy
Benzinga · 5d ago
Weekly Report: what happened at PLX last week (0302-0306)?
Weekly Report · 5d ago
Weekly Report: what happened at PLX last week (0223-0227)?
Weekly Report · 03/02 09:38
More
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

Webull offers Protalix Biotherapeutics Inc stock information, including AMEX: PLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLX stock methods without spending real money on the virtual paper trading platform.